AstraZeneca (LON:AZN) PT Raised to £150

AstraZeneca (LON:AZN) had its target price raised by Berenberg Bank from £130 ($165.54) to £150 ($191.01) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on AZN. Shore Capital restated a buy rating on shares of AstraZeneca in a report on Tuesday, May 21st. UBS Group dropped their price target on shares of AstraZeneca from £107 ($136.25) to GBX 9,900 ($126.07) and set a sell rating on the stock in a research note on Monday, February 12th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research note on Tuesday, May 28th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. Finally, Jefferies Financial Group reiterated a hold rating and issued a £113 ($143.89) price target on shares of AstraZeneca in a research note on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of £120.86 ($153.90).

AstraZeneca Stock Performance

Shares of AZN stock opened at £126 ($160.45) on Friday. AstraZeneca has a 12 month low of GBX 9,461 ($120.48) and a 12 month high of £127.04 ($161.77). The stock has a market cap of £195.30 billion, a PE ratio of 4,038.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.16. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 92.51. The company’s fifty day moving average price is £117.74 and its 200-day moving average price is £108.54.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.